Senores Pharmaceuticals IPO Day 3 Live Updates: Key Highlights, Subscription Status, and Insights

Senores Pharmaceuticals IPO: Subscription Details

December 24, 2024 11:39:12 AM (Day 3)

Senores Pharmaceuticals IPO is offering a total of 1,48,12,723 shares. 

Of these, 

• 44,43,817 shares (30%) are reserved for qualified institutional investors, 
• 22,21,909 shares (15%) for non-institutional investors, 
• 14,81,272 shares (10%) for retail investors, and 
• 66,65,725 shares (45%) to Anchor investors.

As of the IPO’s third day, retail investors had subscribed the most, 54.73x, followed by qualified institutional investors, 0.41x, and non-institutional investors, 43.26x. 

On Day 3, the issue was subscribed 22.1 times with bids for 18,00,27,014 shares against 81,46,998 shares offered. 

Senores Pharmaceuticals IPO: Price Band and Lot Size

The price band is set between ₹372 to ₹391 per share. 

The minimum lot size for an application is 38 shares (1 lot), requiring a minimum investment of ₹14,858 for retail investors. Small Non-Institutional Investors need to invest in at least 14 lots, totalling 532 shares, with a minimum investment of  ₹2,08,012. For large Non-Institutional Investors, the minimum investment is 68 lots, equating to 2,584 shares, for a total of ₹10,10,344.

About Senores Pharmaceuticals

Senores Pharmaceuticals manufactures various pharmaceutical products across therapeutic areas, including antibiotics and anti-fungal treatments. To date, they have launched 55+ products, including Hydroxychloroquine Sulfate tablets, Ketoconazole tablets,  Irbesartan tablets, Risperidone tablets, Topiramate capsules, and more. 

As of March 31st, 2024, the company’s revenue from operations increased by 507% to Rs 214.52 crore from Rs 35.34 crore. 

The funds raised from the IPO will mainly be used to establish new manufacturing facilities, support the working capital requirements, pay off company borrowings, and associated interest, and meet other costs.